Interleukin-6 blockade in ocular inflammatory diseases

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 301-309

  Mesquida, M ^a   Leszczynska, A ^a   Llorenc V ^a   Adan A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Autoimmune diseases; Interleukin 6; Monoclonal antibodies; Tocilizumab; Uveitis

Indexed keywords

ACENOCOUMAROL; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; CYCLOSPORIN; INTERLEUKIN 6; PHENYTOIN; SIMVASTATIN; THEOPHYLLINE; TOCILIZUMAB;

AORTITIS; AQUEOUS HUMOR; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; BACTERIAL INFECTION; CELL DIFFERENTIATION; CHILL; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); DEMYELINATING DISEASE; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; EYE INFLAMMATION; FEVER; GENE INACTIVATION; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; INFECTION; INFUSION RELATED REACTION; IRITIS; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA CYSTOID EDEMA; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; UVEITIS;

AUTOIMMUNE DISEASES; INTERLEUKIN-6; MONOCLONAL ANTIBODIES; TOCILIZUMAB; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; EYE DISEASES; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84897549861     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12295     Document Type: Review

References (70)

1. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10.
2. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23:1-21.
3. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
4. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636.
5. Nishikawa T, Hagihara K, Serada S etal. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180:3492-3501.
6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
7. Fujimoto M, Nakano M, Terabe F etal. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186:32-40.
8. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40:1830-1835.
9. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10:744-755.
10. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-1549.
11. Ishibashi T, Kimura H, Shikama Y etal. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74:1241-1244.
12. Kotake S, Sato K, Kim KJ etal. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11:88-95.
13. Nakahara H, Song J, Sugimoto M etal. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48:1521-1529.
14. Grossman RM, Krueger J, Yourish D etal. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367-6371.
15. Gillespie EF, Raychaudhuri N, Papageorgiou KI etal. Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB. Invest Ophthalmol Vis Sci 2012; 53:7746-7753.
16. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78.
17. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012; 8:1227-1236.
18. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300:2101-2104.
19. Fujimoto M, Serada S, Mihara M etal. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58:3710-3719.
20. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119:296-305.
21. Kitaba S, Murota H, Terao M etal. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180:165-176.
22. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86:592-599.
23. Hohki S, Ohguro N, Haruta H etal. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010; 91:162-170.
24. Haruta H, Ohguro N, Fujimoto M etal. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52:3264-3271.
25. Serada S, Fujimoto M, Mihara M etal. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105:9041-9046.
26. Tanaka T. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy 2013; 5:695-697.
27. Yao X, Huang J, Zhong H etal. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141:125-139.
28. Smolen JS, Beaulieu A, Rubbert-Roth A etal., OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-997.
29. Yokota S, Imagawa T, Mori M etal. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 2008; 371:998-1006.
30. Nishimoto N, Kanakura Y, Aozasa K etal. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627-2632.
31. Adler S, Kolev M, Varisco PA etal. Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy. J Allergy Clin Immunol 2013; 131:1235-1237, 1237.e1.
32. Shima Y, Kuwahara Y, Murota H etal. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxf) 2010; 49:2408-2412.
33. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxf) 2011; 50:1344-1346.
34. Kieffer P, Hinschberger O, Ciobanu E etal. Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review. Rev Med Interne 2014; 35:56-59.
35. Hirano T, Ohguro N, Hohki S etal. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22:298-302.
36. Mesquida M, Molins B, Llorenç V etal. Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol 2013; Jun 1. [Epub ahead of print].
37. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46:3388-3389.
38. Ito H, Takazoe M, Fukuda Y etal. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989-996; discussion 947.
39. Wendling D, Godfrin-Valnet M, Prati C. Treatment of relapsing polychondritis with tocilizumab. J Rheumatol 2013; 40:1232.
40. Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013; 19:400-401.
41. Adán A, Llorenç V, Mesquida M, Pelegrín L. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251:2249-2250.
42. Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 2014; 252:163-164.
43. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012; 39:1294-1295.
44. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011; 19:382-383.
45. Nishida S, Kawasaki T, Kashiwagi H etal. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod Rheumatol 2011; 21:420-422.
46. García-Hernández FJ, González-León R, Castillo-Palma MJ, Ocaña-Medina C, Sánchez-Román J. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxf) 2012; 51:1918-1919.
47. Okuda Y, Ohnishi M, Matoba K etal. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 2014; 24:137-143.
48. Drobyski WR, Pasquini M, Kovatovic K etal. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17:1862-1868.
49. Kaly L, Rosner I. Tocilizumab-a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26:157-165.
50. Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013; 45:357-363.
51. Ogata A, Morishima A, Hirano T etal. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 2011; 70:1164-1165.
52. Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye and ear experience and review of previous studies. Ocul Immunol Inflamm 2004; 12:193-201.
53. Curnow SJ, Falciani F, Durrani OM etal. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005; 46:4251-4259.
54. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011; 31:733-744.
55. Caspi RR, Roberge FG, McAllister CG etal. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 1986; 136:928-933.
56. Amadi-Obi A, Yu CR, Liu X etal. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-718.
57. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
58. Yoshimura T, Sonoda KH, Ohguro N etal. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxf) 2009; 48:347-354.
59. Adán A, Mesquida M, Llorenç V etal. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251:2627-2632.
60. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012; 30 (3 Suppl. 72):S73-75.
61. Oshitari T, Kajita F, Tobe A etal. Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med 2012; 2012:968180.
62. Shibuya M, Fujio K, Morita K, Harada H, Kanda H, Yamamoto K. Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis. Mod Rheumatol 2013; 23:577-581.
63. Kieseier BC, Stüve O, Dehmel T etal. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70:390-393.
64. Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 2012; 250:1521-1526.
65. Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A etal. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity. Endocr Res 2012; 37:89-95.
66. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 2014; 43:458-469.
67. Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 2013; 7:653-666.
68. Koike T, Harigai M, Inokuma S etal. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014; 41:15-23.
69. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxf) 2011; 50:552-562.
70. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxf) 2013; Dec 17. [Epub ahead of print].